Maria Daniela Sarquis

Dr. Maria Daniela Sarquis

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Rafail C. ChristodoulouRafail C. Christodoulou
Rafail C. Christodoulou
GVGeorgios Vamvouras
Georgios Vamvouras
PPPlaton S. Papageorgiou
Platon S. Papageorgiou
MSMaria Daniela Sarquis
Maria Daniela Sarquis
VPVasileia Petrou
Vasileia Petrou
EVEvros Vassiliou
Evros Vassiliou
Background/Objectives: Hippocampal atrophy indicates Alzheimer’s disease (AD) progression and guides follow-up and trial enrichment. Identifying high-risk patients is crucial for optimizing care, but accessible, interpretable machine-learning models (ML) are limited. We developed an explainable ML model using clinical data and CSF erythrocyte load (CTRED) to classify adults with AD as high- or low-risk based on hippocampal volume decline. Methods: Included ADNI participants with ≥2 MRIs, baseline lumbar puncture, and vital signs within 6 months of MRI (n = 26). The outcome was the Annual Percentage Change (APC) in hippocampal volume, classified as low or high risk. Predictors were standardized; models included SVM, logistic regression, and Ridge Classifier, tuned and tested on a set (n = 6). Thresholds were based on out-of-fold predictions under a 10–90% positive rate. Explainability used PFI and SHAP for per-patient contributions. Results: All models gave identical classifications, but discrimination varied: Ridge AUC = 1.00, logistic = 0.889, and SVM = 0.667. PFI highlighted MAPres and sex as main signals; CTRED contributed, and age had a minor impact. Conclusions: The explainable ML model with clinical data and CTRED can stratify AD patients by hippocampal atrophy risk, aiding follow-up and vascular assessment planning rather than treatment decisions. Validation in larger cohorts is needed. This is the first ML study to use CSF erythrocyte load to predict hippocampal atrophy risk in AD.

17 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Rafail C. ChristodoulouRafail C. Christodoulou
Rafail C. Christodoulou
GVGeorgios Vamvouras
Georgios Vamvouras
MSMaria Daniela Sarquis
Maria Daniela Sarquis
VPVasileia Petrou
Vasileia Petrou
PPPlaton S. Papageorgiou
Platon S. Papageorgiou
EVEvros Vassiliou
Evros Vassiliou
Background/Objectives: Cerebrospinal fluid erythrocyte load (CTRED) reflects occult red-blood-cell ingress into brain/CSF and consequent heme–iron exposure, a toxic pathway relevant to Alzheimer’s disease (AD). We aimed to develop explainable machine learning (ML) models that classify high vs. low CTRED from routine, largely non-invasive inputs, and to position a blood-first workflow leveraging contemporary plasma amyloid–tau biomarkers. Methods: Twenty-six ADNI participants were analyzed. Inputs were age, sex, mean arterial pressure (MAPres), amyloid (Aβ42), total tau, phosphorylated tau, and hippocampal atrophy rate (APC) derived from longitudinal MRI. APC was computed from normalized hippocampal volumes. CTRED was binarized at the median (0 vs. >0). Data were split into train (n = 20) and held-out test (n = 6). Five classifiers (linear SVM, ridge, logistic regression, random forests, and MLP) were trained in leakage-safe pipelines with stratified five-fold cross-validation. To provide a comprehensive assessment, we presented the contribution AUC, thresholded performance metrics, summarized model performance, and the permutation feature importance (PFI). Results: On the test set, SVM, ridge, logistic regression, and random forests achieved AUC = 1.00, while the MLP achieved AUC = 0.833. Across models, PFI consistently prioritized p-tau/tau, Aβ42, and MAPres; age, sex, and APC contributed secondarily. The attribution profile aligns with mechanisms linking BBB dysfunction and amyloid-related microvascular fragility with tissue vulnerability to heme–iron. Conclusions: In this proof-of-concept study, explainable ML predicted CTRED from routine variables with biologically coherent drivers. Although ADNI measurements were CSF-based and the sample was small, the framework is non-invasive by adding plasma p-tau217/Aβ1–42 for amyloid, tau inputs, and integrating demographics, hemodynamic context, and MRI. External, plasma-based validation in larger cohorts is warranted, alongside extension to MCI and multimodal correlation (QSM, DCE-MRI) to establish clinically actionable CTRED thresholds.

27 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Rafail C. ChristodoulouRafail C. Christodoulou
Rafail C. Christodoulou
GVGeorgios Vamvouras
Georgios Vamvouras
MSMaria Daniela Sarquis
Maria Daniela Sarquis
VPVasileia Petrou
Vasileia Petrou
PPPlaton S. Papageorgiou
Platon S. Papageorgiou
SPSokratis G. Papageorgiou
Sokratis G. Papageorgiou
Background/Objectives: Alzheimer’s disease (AD) exhibits clinical and biological variability. This study aimed to identify MRI-defined subtypes reflecting distinct biological pathways of neurodegeneration and cognitive decline. Methods: We applied principal component analysis followed by k-means clustering (k = 3) on volumetric MRI data from 924 participants and validated clusters using cerebrospinal fluid (CSF) biomarkers (Aβ42, total tau, p-tau, CTRED, MAPres, glucose, CTWHITE). Results: Three major phenotypes emerged: (1) a tau/vascular limbic subtype with pronounced hippocampal and amygdala atrophy and elevated tau and CTRED levels; (2) a volume-preserved, low-amyloid subtype consistent with early-stage or cognitively resilient AD; and (3) a diffuse-atrophy subtype with high amyloid and tau burden and ventriculomegaly. Comparative analysis revealed progressive biological shifts from amyloid accumulation to tau aggregation and vascular compromise across these clusters. Conclusions: MRI-based clustering validated by CSF biomarkers delineates biologically meaningful AD endophenotypes. The results suggest a gradual cognitive decline driven by amyloid–tau–vascular interactions, supporting multimodal phenotyping as a practical approach for precision staging and intervention.

10 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Rafail C. ChristodoulouRafail C. Christodoulou
Rafail C. Christodoulou
PPPlaton S. Papageorgiou
Platon S. Papageorgiou
MSMaria Daniela Sarquis
Maria Daniela Sarquis
LRLudwing Rivera
Ludwing Rivera
CGCelimar Morales Gonzalez
Celimar Morales Gonzalez
MGMichalis F Georgiou
Michalis F Georgiou
Background: Alzheimer’s disease (AD) remains the leading cause of dementia worldwide, with anti-amyloid monoclonal antibodies (MABs) marking a significant advance as the first disease-modifying therapies. Their use, however, is limited by amyloid-related imaging abnormalities (ARIA), which appear as vasogenic edema or effusion (ARIA-E) and hemosiderin-related changes (ARIA-H) on MRI. Variability in imaging protocols, subtle early findings, and the lack of standardized risk models challenge detection and management. Methods: This narrative review summarizes current artificial intelligence (AI) applications for ARIA detection and risk prediction. A comprehensive literature search across PubMed, Embase, and Scopus identified studies focusing on MRI-based AI analysis, lesion quantification, and predictive modeling. Results: The evidence is organized into six thematic domains: ARIA definitions, imaging challenges, foundations of AI in neuroimaging, detection tools, predictive frameworks, and future perspectives. Conclusions: AI offers promising avenues to standardize ARIA evaluation, improve lesion quantification, and enable individualized risk prediction. Progress will depend on multicenter datasets, shared frameworks, and prospective validation. Ultimately, AI-driven neuroimaging may transform how treatment-related complications are monitored in the era of anti-amyloid therapy.

3 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Rafail C. ChristodoulouRafail C. Christodoulou
Rafail C. Christodoulou
RPRafael Pitsillos
Rafael Pitsillos
VPVasileia Petrou
Vasileia Petrou
MSMaria Daniela Sarquis
Maria Daniela Sarquis
PPPlaton S. Papageorgiou
Platon S. Papageorgiou
ESElena E Solomou
Elena E Solomou
Background/Objectives: Central nervous system (CNS) involvement in acute myeloid leukemia (AML) is a rare but important complication linked to poor outcomes. Diagnosing it is difficult because neurological symptoms are often subtle or nonspecific, and conventional cytology and imaging have limitations. This review summarizes current evidence on the neuroradiologic features of CNS infiltration in AML and explores the growing role of artificial intelligence (AI) in enhancing detection and characterization. Methods: A thorough narrative review was conducted using PubMed, Scopus, and Embase, employing key terms related to AML, CNS involvement, MRI, CT, PET, AI, machine learning, deep learning, and radiomics. Of several thousand records, 138 relevant studies were selected and analyzed across four main areas: neuroradiologic patterns, imaging biomarkers, AI and radiomics applications, and emerging computational trends. Results: Imaging findings in AML mainly include myeloid sarcomas (isointense on T1, hyperintense on T2/FLAIR, restricted diffusion) and leptomeningeal enhancement. Secondary ischemic or hemorrhagic lesions may indicate brain leukocytosis. MRI proved more sensitive than CT, while PET/CT helped detect extramedullary disease. Recent AI and radiomics models showed high tumor classification and prognosis accuracy in similar CNS conditions, indicating significant potential for application in AML-CNS. Conclusions: Combining AI-based image analysis with multimodal neuroimaging could significantly improve diagnostic accuracy and personalized treatment for CNS involvement in AML. Progress is still challenged by the rarity of the condition and the lack of large, annotated datasets.

9 March 2026 in Abdominal Radiology
Verified
Journal Article
Closed access
LALucas Alves
Lucas Alves
GMGuilherme Franceschini Machado
Guilherme Franceschini Machado
GMGiovanna Cristina de Castro Martin
Giovanna Cristina de Castro Martin
MLMaria Julia Lemos
Maria Julia Lemos
MSMaria Daniela Sarquis
Maria Daniela Sarquis
ATAtul Kumar Taneja
Atul Kumar Taneja